Verily Raises $300 Million in Latest Funding Round
Verily, an Alphabet company focused on advancing precision health through AI technology, announced a successful funding round on March 18, 2026, securing $300 million. The financing was led by Series X Capital, with participation from Alphabet, UCHealth, and the University of Colorado Anschutz.
Strategic Investment to Propel Precision Health Initiatives
Verily is renowned for its AI-native platform that transforms complex health data into actionable insights aimed at improving research, care, and patient outcomes. This latest round of investment will enable the company to further its precision health AI strategy, enhancing its ability to deliver personalized, predictive, and precise healthcare solutions.
Key Investors and Stakeholder Changes
Series X Capital spearheaded the funding round, joined by notable investors such as Alphabet, UCHealth, and the University of Colorado Anschutz. Notably, this round marks a shift in Alphabet's role, as it becomes a significant minority investor in Verily, relinquishing its previously held controlling stake.
Utilization of Funds
While specific plans for the $300 million investment were not detailed, the funding is expected to support Verily's ongoing development of its precision health AI solutions. This includes leveraging multimodal health data to drive innovation in healthcare technologies and services.
Company Location and Operations
Based in Dallas, Texas, Verily operates at the intersection of technology, data science, and healthcare. The company continues to expand its influence in the precision health space, aiming to transform healthcare delivery and outcomes through advanced AI capabilities.
For more information on Verily and its initiatives, visit their official website.